Technical Analysis for 0H22 - Bioinvent International AB
| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Weak or Absent | N/A | N/A | Down |
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| Hot IPO Pullback | Bullish Swing Setup | 0.00% | |
| Narrow Range Bar | Range Contraction | 0.00% | |
| Narrow Range Bar | Range Contraction | -1.65% | |
| Shooting Star Candlestick | Bearish | -5.67% | |
| Narrow Range Bar | Range Contraction | -5.67% | |
| Doji - Bearish? | Reversal | -5.67% | |
| Stochastic Buy Signal | Bullish | 3.85% | |
| Narrow Range Bar | Range Contraction | 3.85% | |
| Narrow Range Bar | Range Contraction | 4.24% | |
| New 52 Week Closing Low | Bearish | 7.40% |
Free Daily (Stock) Chart Reading
Bioinvent International AB Description
BioInvent International AB (publ), a clinical-stage company, discovers, researches, and develops immuno-modulatory antibodies for the treatment of cancer in Sweden, Europe, the United States, and internationally. Its drug candidate is BI-1206 for the treatment of non-Hodgkin lymphoma and solid tumors. The company also develops tumor associated myeloid cells; cancer-associated regulatory T cells, which modulate the immune system; BT-001 for solid tumors; and BI-1808 and BI-1910, which are anti-TNFR2 antibodies for the treatment of solid tumors and cutaneous T-cell lymphoma. It has a partnership and collaboration with Transgene to co-develop BT-001 multi-functional oncolytic viruses for treatment of solid tumors; and collaboration and supply agreement with Merck to evaluate BT-001 in combination with Keytruda, and in BI-1808. BioInvent International AB (publ) was incorporated in 1996 and is based in Lund, Sweden.
Classification
Keywords: Cancer Clinical Medicine Drugs Tumor Antibodies Monoclonal Antibodies Treatment Of Cancer Breakthrough Therapy Cancer Treatments Antineoplastic Drugs Bristol Myers Squibb Solid Tumors
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 48.575 |
| 52 Week Low | 26.35 |
| Average Volume | 287,896 |
| 200-Day Moving Average | 0.00 |
| 50-Day Moving Average | 0.00 |
| 20-Day Moving Average | 35.20 |
| 10-Day Moving Average | 28.83 |
| Average True Range | 2.11 |
| RSI (14) | 0.00 |
| ADX | 0.0 |
| +DI | 30.12 |
| -DI | 57.26 |
| Chandelier Exit (Long, 3 ATRs) | 42.25 |
| Chandelier Exit (Short, 3 ATRs) | 32.68 |
| Upper Bollinger Bands | 50.06 |
| Lower Bollinger Band | 20.33 |
| Percent B (%b) | 0.27 |
| BandWidth | 84.49 |
| MACD Line | -5.25 |
| MACD Signal Line | -4.22 |
| MACD Histogram | -1.0297 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 28.60 | ||||
| Resistance 3 (R3) | 28.57 | 28.43 | 28.55 | ||
| Resistance 2 (R2) | 28.43 | 28.36 | 28.45 | 28.53 | |
| Resistance 1 (R1) | 28.37 | 28.31 | 28.40 | 28.40 | 28.52 |
| Pivot Point | 28.23 | 28.23 | 28.25 | 28.25 | 28.23 |
| Support 1 (S1) | 28.17 | 28.16 | 28.20 | 28.20 | 28.08 |
| Support 2 (S2) | 28.03 | 28.11 | 28.05 | 28.07 | |
| Support 3 (S3) | 27.97 | 28.03 | 28.05 | ||
| Support 4 (S4) | 28.00 |
